GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » EV-to-EBITDA

Biotage AB (Biotage AB) EV-to-EBITDA : 25.20 (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biotage AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biotage AB's enterprise value is $1,184.0 Mil. Biotage AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $47.0 Mil. Therefore, Biotage AB's EV-to-EBITDA for today is 25.20.

The historical rank and industry rank for Biotage AB's EV-to-EBITDA or its related term are showing as below:

BITGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.18   Med: 26.73   Max: 50.63
Current: 26

During the past 13 years, the highest EV-to-EBITDA of Biotage AB was 50.63. The lowest was 6.18. And the median was 26.73.

BITGF's EV-to-EBITDA is ranked worse than
77% of 487 companies
in the Medical Devices & Instruments industry
Industry Median: 15.18 vs BITGF: 26.00

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Biotage AB's stock price is $14.63. Biotage AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.298. Therefore, Biotage AB's PE Ratio for today is 49.09.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biotage AB EV-to-EBITDA Historical Data

The historical data trend for Biotage AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB EV-to-EBITDA Chart

Biotage AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.13 29.51 49.51 26.47 22.28

Biotage AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.47 28.12 22.91 22.28 28.77

Competitive Comparison of Biotage AB's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Biotage AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biotage AB's EV-to-EBITDA falls into.



Biotage AB EV-to-EBITDA Calculation

Biotage AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1184.015/46.984
=25.20

Biotage AB's current Enterprise Value is $1,184.0 Mil.
Biotage AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotage AB  (OTCPK:BITGF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biotage AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.63/0.298
=49.09

Biotage AB's share price for today is $14.63.
Biotage AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.298.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biotage AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biotage AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB (Biotage AB) Business Description

Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (Biotage AB) Headlines

From GuruFocus

Biotage AB (publ) Year-end report January - December 2021

By PRNewswire PRNewswire 02-11-2022

Biotage Awarded Gold Sustainability Medal by EcoVadis

By PRNewswire PRNewswire 02-24-2022

Biotage - Change in number of shares and votes

By PRNewswire PRNewswire 10-29-2021

Notice of Annual General Meeting in Biotage AB (publ)

By PRNewswire PRNewswire 04-28-2020

Biotage appoints Nomination Committee

By PRNewswire PRNewswire 09-24-2020

Biotage AB (publ) Interim Report January - March 2020

By PRNewswire PRNewswire 04-28-2020